The Institute of Biomedical Research runs clinical trials that pair new science with the care team you already know — starting with a new complementary treatment for autoimmune hepatitis.
Every trial we run is delivered through your existing primary care channels, with monitoring built around your standard testing schedule.
Testing whether two common, already-approved drugs can treat autoimmune hepatitis as well as steroids do — with fewer of the drawbacks, and a potential option for the 20% of patients who are steroid-resistant.
Add a short description of this trial here — what it's testing, who it's for, and why it matters.
Our team is preparing further trials across the Institute. Check back, or contact us to hear first.
Based at the University of Birmingham, we design trials around treatments that are already trusted — so patients can take part without stepping outside their existing care.
We build complementary standards of care for patients who don't respond well to first-line treatment, working from pre-approved, commonly used pharmaceuticals rather than starting from scratch.
Many first-line treatments work for most patients, but not all. Our trials focus on the people left behind by the current standard of care, without asking them to take on unfamiliar risk.
Contact us using the details below, or scan the QR code on your phone to visit our contact page.
Note: the email, phone number and QR code here are placeholders carried over from the trial brochure draft — swap in the Institute's real contact details before this goes live.